Neurocrine Biosciences, Inc. (NBIX)
156.14
-0.62
(-0.40%)
USD |
NASDAQ |
Sep 02, 10:34
Neurocrine Biosciences Free Cash Flow : 812.00M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 812.00M |
| March 31, 2026 | 831.30M |
| December 31, 2025 | 748.70M |
| September 30, 2025 | 593.10M |
| June 30, 2025 | 528.70M |
| March 31, 2025 | 492.20M |
| December 31, 2024 | 557.20M |
| September 30, 2024 | 440.10M |
| June 30, 2024 | 494.60M |
| March 31, 2024 | 614.40M |
| December 31, 2023 | 361.60M |
| September 30, 2023 | 384.70M |
| June 30, 2023 | 280.80M |
| March 31, 2023 | 237.30M |
| December 31, 2022 | 322.90M |
| September 30, 2022 | 177.00M |
| June 30, 2022 | 132.60M |
| March 31, 2022 | 102.20M |
| December 31, 2021 | 233.10M |
| September 30, 2021 | 322.20M |
| June 30, 2021 | 248.20M |
| March 31, 2021 | 263.50M |
| December 31, 2020 | 217.60M |
| September 30, 2020 | 232.94M |
| June 30, 2020 | 345.12M |
| Date | Value |
|---|---|
| March 31, 2020 | 290.64M |
| December 31, 2019 | 137.31M |
| September 30, 2019 | 82.01M |
| June 30, 2019 | 44.28M |
| March 31, 2019 | 0.408M |
| December 31, 2018 | 76.55M |
| September 30, 2018 | 70.31M |
| June 30, 2018 | 1.634M |
| March 31, 2018 | -62.84M |
| December 31, 2017 | -101.27M |
| September 30, 2017 | -171.44M |
| June 30, 2017 | -191.11M |
| March 31, 2017 | -159.06M |
| December 31, 2016 | -110.29M |
| September 30, 2016 | -94.35M |
| June 30, 2016 | -81.45M |
| March 31, 2016 | -51.42M |
| December 31, 2015 | -39.93M |
| September 30, 2015 | -39.65M |
| June 30, 2015 | -33.13M |
| March 31, 2015 | -57.19M |
| December 31, 2014 | -48.75M |
| September 30, 2014 | -44.07M |
| June 30, 2014 | -42.52M |
| March 31, 2014 | -42.03M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Amarin Corp. Plc | 15.55M |
| Liquidia Corp. | 150.69M |
| Incyte Corp. | 1.890B |
| Halozyme Therapeutics, Inc. | 806.22M |
| Iovance Biotherapeutics, Inc. | -296.40M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 78.00M |
| Cash from Investing (Quarterly) | -135.40M |
| Cash from Financing (Quarterly) | 121.80M |
| Free Cash Flow Per Share (Quarterly) | 0.6737 |
| Free Cash Flow to Equity (Quarterly) | 74.60M |
| Free Cash Flow to Firm (Quarterly) | 72.78M |
| Free Cash Flow Yield | 5.03% |